FDA on OTC switches
This article was originally published in The Tan Sheet
Executive Summary
Rx-to-OTC switches "are not on the ropes," FDA Office of Drug Evaluation I Director Robert Temple, MD, said at a Dec. 6 briefing with trade press, despite recent FDA advisory committee recommendations against approval of OTC switches for the baldness remedy Rogaine and the H[2] antagonists cimetidine and famotidine. "You shouldn't assume that [those switches] are not going anywhere," Temple said. He added that the committee recommendations "were perceived as much more adverse" than they actually are
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning